Stockscreener 앱 받기
0.7815
9.54%
-0.0824
시간 외 거래:
.79
0.0085
+1.09%
전일 마감가:
$0.8639
열려 있는:
$0.865
하루 거래량:
324.49K
Relative Volume:
0.34
시가총액:
$54.18M
수익:
-
순이익/손실:
$-115.51M
주가수익비율:
-0.385
EPS:
-2.03
순현금흐름:
$-95.89M
1주 성능:
-22.62%
1개월 성능:
+13.26%
6개월 성능:
-56.82%
1년 성능:
-55.60%
1일 변동 폭
$0.7702
$0.8899
1주일 범위
$0.7702
$1.05
52주 변동 폭
$0.63
$3.1399
보 바이오파마 Stock (VOR) Company Profile
명칭
Vor Biopharma Inc
전화
617-655-6580
주소
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
VOR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| VOR | 0.7815 | 54.18M | 0 | -115.51M | -95.89M | -2.03 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
보 바이오파마 Stock (VOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-26 | 개시 | Wedbush | Outperform |
| 2022-04-27 | 개시 | Goldman | Neutral |
| 2021-12-17 | 개시 | H.C. Wainwright | Buy |
| 2021-12-03 | 개시 | Robert W. Baird | Outperform |
| 2021-12-02 | 개시 | Oppenheimer | Outperform |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-03-03 | 개시 | Evercore ISI | Outperform |
| 2021-03-02 | 개시 | Goldman | Sell |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
보 바이오파마 주식(VOR)의 최신 뉴스
VOR Biopharma's SWOT analysis: stock shows promise amid clinical progress - Investing.com Nigeria
Vor Bio to Participate in the Stifel 2024 Healthcare Conference - GlobeNewswire
Vor Bio to Present at Stifel Healthcare Conference, Host Key Investor Meetings | VOR Stock News - StockTitan
Robert W. Baird Lowers Vor Biopharma (NYSE:VOR) Price Target to $14.00 - Defense World
Vor Biopharma (NYSE:VOR) Given “Buy” Rating at HC Wainwright - Defense World
Vor Biopharma’s (VOR) “Outperform” Rating Reiterated at Wedbush - Defense World
Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush - MarketBeat
Vor Biopharma (NYSE:VOR) Earns Buy Rating from HC Wainwright - MarketBeat
Vor Biopharma (NYSE:VOR) Price Target Lowered to $14.00 at Robert W. Baird - MarketBeat
Vor Biopharma Reports Q3 2024 Financial Results - TipRanks
Vor Biopharma : Bio Corporate Presentation November 2024 - Marketscreener.com
Vor Biopharma Inc. (VOR) Reports In-Line Q3 EPS - StreetInsider.com
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
Vor Biopharma : SITC – 2024 – POSTER PRESENTATION 1092 - Marketscreener.com
Vor Biopharma : ESGCT – 2024 – Oral Presentation OR085 - Marketscreener.com
Allogeneic Hematopoietic Stem Cell Transplant Market to - GlobeNewswire
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline
Closing Strong: Vor Biopharma Inc (VOR) Ends at 0.64, Down -3.04 from Last Close - The Dwinnex
Recent Insider Activity Could Benefit Vor Biopharma Inc (VOR) - Knox Daily
Analyzing Chemours Company (CC) After Recent Trading Activity - Knox Daily
Insider Selling Buzz: Vor Biopharma Inc [VOR] CHIEF MEDICAL OFFICER Attar Eyal C. sold 14,645 shares of the company – Knox Daily - Knox Daily
Closing Figures: Vor Biopharma Inc (VOR)’s Positive Finish at 0.69, Up 2.80 - The Dwinnex
An Analysis of Vor Biopharma Inc (VOR)’s Potential Price Growth - Knox Daily
Vor Biopharma Inc (VOR) Stock: From Low to High in 52 Weeks - The InvestChronicle
How does Vor Biopharma Inc (VOR) change from a tortoise to a hare? - SETE News
Vor Biopharma's SWOT analysis: oncology stock shows promise amid challenges - Investing.com
Vor Bio appoints new CFO amid clinical advancements - Investing.com India
Vor Biopharma Inc (VOR) deserves closer scrutiny - US Post News
Vor Biopharma Inc. Appoints Han Choi as Chief Financial Officer - Marketscreener.com
Metric Analysis: Vor Biopharma Inc (VOR)’s Key Ratios in the Limelight - The Dwinnex
Vor Biopharma Appoints New CFO, Enhances Leadership Team - TipRanks
Vor Biopharma (VOR) Appoints Han Choi as CFO - StreetInsider.com
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer - GlobeNewswire
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer - GlobeNewswire Inc.
Vor Biopharma stock plunges to 52-week low of $0.69 - Investing.com
Vor Biopharma stock plunges to 52-week low of $0.69 By Investing.com - Investing.com UK
Potential Price Increase for Vor Biopharma Inc (VOR) After Recent Insider Activity - Knox Daily
VOR’s Stock Market Adventure: -65.78% YTD Growth Amidst Volatility - The InvestChronicle
Investing in Vor Biopharma Inc (VOR) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
VHS BEYOND Movie - One News Page
Vornado Realty Trust stock outperforms competitors on strong trading day - MarketWatch
Verona Pharma Plc ADR [VRNA] President and CEO makes an insider sale of 600,000 shares worth $2.25 million. - Knox Daily
Vapotherm director James Liken sells $15,956 in stock, disposes of additional $119,481 worth - Investing.com
Shudder Streaming Seventh ‘V/H/S’ Horror Movie Franchise Release on Oct. 4 - Media Play News
Rev Up Your Chainsaw and Sit Down to Watch this V/H/S/Beyond Trailer - Reactor
V/H/S Beyond Archives - Media Play News
Found Footage Frights Abound in Official Trailer for V/H/S/BEYOND - Daily Dead
‘V/H/S/BEYOND’ Shows Off Sci-Fi Anthology Terror In New Trailer - That Hashtag Show
V/H/S Prepares You for Insanity with This Brand New Trailer - iHorror Movie News
V/H/S/BEYOND Trailer Unleashed For Halloween Season - Starburst Magazine
Horror meets sci-fi in V/H/S/Beyond trailer as early reviews call it the "strongest collection of tales in V/H/S history" - Gamesradar
보 바이오파마 (VOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):